Attendee search 

China largest PE fund which total size is over ten billion RMB.

Viva BioInnovator ("VBI") is the investment division of Viva Biotech Holdings (1873.HK). We are solely dedicated to the identification and success of early-stage, biotech start-ups for Viva’s incubation, equity-for-service, and investment platforms. Our commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.

Our vision is: Curing cancer, pushing science to its limits and contributing to safe medical devices around the world!

As a medical device software specialist, we help MedTech startups get to their next milestone faster and safer. We have 20 years of experience and 220 in-house engineers to back you up and get you to the finish line - getting your device to market.
see less

Kaitai is a biotech venture fund with about 40 biotech portfolio companies. Kaitai's fund size is about 7 billions dollars. They are positively looking for cutting edge technologies.

FEBICO (Far East Bio-Tec. Co., Ltd.) was established in 1976. We have three main business segments: New Drug Development, Diagnostic Reagents, and Dietary Supplement .
We develop an anti-virus platform, FEM, to develop potential drug candidates.
We focus on developments of botanical drugs and biologics to resolve the unmet medical needs such as inflammation diseases (lung injury, liver inflammation, liver fibrosis), hepatitis B, and herpes.

Humanwell is the market leader in anaesthetics/analgesics, fertility regulation drugs, and Uyghur medicine in Asia. It is also a major player with expanding product portfolio and market shares in treating central nerve system, respiratory and dermatological diseases in China.

Currently, TopWin Pharma. has developed to a high-tech group involving the biological and chemical medicine. TopWin Pharmaceutical Group's business has covered all aspects of R&D of new drugs, including clinical research, registration, production and sale. With the mission of "bringing benefits to mankind through innovation and technology", Topwin Group has been cooperating with well-known domestic and international drug R&D institutions to build TopWin Pharma. into a leading domestic and world-class pharmaceutical enterprise.

iosion is a global biotechnology company focusing on the discovery and clinical development of innovative biologicals for unmet medical needs. Leveraging our proprietary H³ (High-throughput High-content High-efficiency) antibody platform and SynAb™ technology, Biosion is able to undertake a deep discovery of antibody drug candidates with superior properties, multiple differential choices, and diversified clinical applications. Based on its integrated antibody discovery engine and fueled by our corporate motto of "Innovation for Cures", Biosion is committed to bring next generation innovative drugs to patients around the world.

During the past several years, Biosion team has successfully built up multiple therapeutic antibody discovery pipelines for in-house development and for collaboration with our partners, thus enabling us to accelerate and broaden our innovative drug development capabilities for delivering novel drugs to patients in needs.

VC investment focus on healthy care

HEC Pharm is the pharmaceutical subsidiaries of HEC Group. There has been a public company listed in Hong Kong in HEC Pharm, and another company will be listed in Shanghai next year.

HEC Pharm focuses on the development and commercialization of pharmaceuticals for the therapeutics of anti-infectious diseases, metabolism disorders and oncology. We are hunting for the opportunities of co-development and in-license of the candidates with the potential therapeutics in previous fields.